Sunifiram is a member of a class of nootropics called ampakines. Sunifiram is derived from the popular nootropic piracetam, and may possess a much greater magnitude of potency . Ampakines are thought to interact with AMPA receptors in the brain . AMPA receptors affect glutamate, which is your body’s most prominent neurotransmitter . First developed in the year 2000, Sunifiram’s usage is rapidly growing in popularity as anecdotal reports of its powerful cognitive enhancement impact are spreading .
1. Martini, E., Salvicchi, A., Ghelardini, C., Manetti, D., Dei, S., Guandalini, L., et al. (2009).Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers. Bioorganic & medicinal chemistry,17(21), 7606-7614.
2. Ghelardini, C., Galeotti, N., Gualtieri, F., Romanelli, M., Bucherelli, C., Baldi, E., et al. (2002). DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer.Naunyn-Schmiedeberg's archives of pharmacology, 365(6), 419-426.
3. Gualtieri, F., Manetti, D., Romanelli, M., & Ghelardini, C. (2002). Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Current pharmaceutical design, 8(2), 125-138.